Related Experiment Video
Updated: Feb 16, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies
Marie Jazmín Sarabia-Sánchez1, Pedro Josué Trejo-Soto2, José Miguel Velázquez-López3
1Facultad de Medicina y Nutrición, Universidad Juárez del Estado de Durango, Av. Universidad y Fanny Anitúa S/N, Durango, Durango C.P. 34000, Mexico. marie_sarabia@hotmail.com.
Abstract:
The Atlas of Diabetes reports 415 million diabetics in the world, a number that has surpassed in half the expected time the twenty year projection. Type 2 diabetes is the most frequent form of the disease; it is characterized by a defect in the secretion of insulin and a resistance in its target organs. In the search for new antidiabetic drugs, one of the principal strategies consists in promoting the action of insulin. In this sense, attention has been centered in the protein tyrosine phosphatase 1B (PTP1B), a protein whose overexpression or increase of its activity has been related in many studies with insulin resistance. In the present work, a chemical library of 250 compounds was evaluated to determine their inhibition capability on the protein PTP1B. Ten molecules inhibited over the 50% of the activity of the PTP1B, the three most potent molecules were selected for its characterization, reporting Ki values of 5.2, 4.2 and 41.3 µM, for compounds 1, 2, and 3, respectively. Docking and molecular dynamics studies revealed that the three inhibitors made interactions with residues at the secondary binding site to phosphate, exclusive for PTP1B. The data reported here support these compounds as hits for the design more potent and selective inhibitors against PTP1B in the search of new antidiabetic treatment.
Insights
Researchers identified three potent compounds that inhibit protein tyrosine phosphatase 1B (PTP1B), a key target for developing new type 2 diabetes treatments. These PTP1B inhibitors show promise for future antidiabetic drug design.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Type 2 diabetes affects over 415 million people globally, exceeding projections.
- Insulin resistance and defective insulin secretion characterize type 2 diabetes.
- Protein tyrosine phosphatase 1B (PTP1B) is a validated target for enhancing insulin action.
Purpose of the Study:
- To screen a chemical library for novel PTP1B inhibitors.
- To identify lead compounds for the development of new antidiabetic drugs.
Main Methods:
- Screening of 250 compounds for PTP1B inhibition.
- Characterization of the most potent inhibitors, including kinetic analysis (Ki values).
- Computational studies: docking and molecular dynamics simulations.
Main Results:
- Ten compounds inhibited PTP1B activity by over 50%.
- Three potent inhibitors were identified with Ki values of 5.2, 4.2, and 41.3 µM.
- Inhibitors interacted with residues at PTP1B's unique secondary phosphate-binding site.
Conclusions:
- The identified compounds are promising hits for designing selective PTP1B inhibitors.
- These findings support the development of novel antidiabetic therapeutics targeting PTP1B.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases

